[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100410281":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":34,"locations":44,"responsibleParty":84,"collaborators":10,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":10,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":10,"studyType":99,"phases":10,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"Proteocyte Diagnostics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Oral Mucosal Biopsies With or Without Evidence of Epithelial Dysplasia",null,"No evidence of dysplasia\n\nMild dysplasia\n\nModerate dysplasia\n\nSevere dysplasia",[13,14],"Procedure: Standard of Care Histopathology","Procedure: STRATICYTE Assessment",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"PROCEDURE","Standard of Care Histopathology","Assessment for mild, moderate, or severe dysplasia, and risk of progression to oral cancer",[9],[22],"H&E assessment for dysplasia grade",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"STRATICYTE Assessment","Assessment for risk of progression to oral cancer",[9],[28],"S100A7 Immunohistochemistry Signature-based Assessment",[30],{"name":31,"affiliation":32,"role":33},"Mark Darling, MSc, MChD","Western University","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Jason Hwang, PhD","CONTACT","(647) 255-1370","jhwang@proteocyte.com",{"name":31,"role":37,"phone":41,"phoneExt":42,"email":43},"(519) 661-2111","86399","mark.darling@schulich.uwo.ca",[45,63,72],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Kingsway Oral & Maxillofacial Surgery","RECRUITING","Edmonton","Alberta","T5M 3Z7","Canada","CA",{"type":54,"coordinates":55},"Point",[56,57],-113.46871,53.55014,{"lat":57,"lon":56},[60,62],{"name":61,"role":37,"phone":10,"phoneExt":10,"email":10},"Tim McGaw, DDS, MSc, MD",{"name":61,"role":33,"phone":10,"phoneExt":10,"email":10},{"facility":64,"status":47,"city":48,"state":49,"zip":65,"country":51,"countryCode":52,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},"University of Alberta","T6G 1C9",{"type":54,"coordinates":67},[56,57],{"lat":57,"lon":56},[70,71],{"name":61,"role":37,"phone":10,"phoneExt":10,"email":10},{"name":61,"role":33,"phone":10,"phoneExt":10,"email":10},{"facility":32,"status":47,"city":73,"state":74,"zip":75,"country":51,"countryCode":52,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"London","Ontario","N6A 5C1",{"type":54,"coordinates":77},[78,79],-81.23304,42.98339,{"lat":79,"lon":78},[82,83],{"name":31,"role":37,"phone":10,"phoneExt":10,"email":10},{"name":31,"role":33,"phone":10,"phoneExt":10,"email":10},{"type":85,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100410281","early-prediction-of-oral-cancer-by-s100a7-immunohistochemistry-signature-based-assessment-100410281",false,"NCT04622462","Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment","A Multi-Centre Prospective Community-Based Observational Study on Prediction of Malignant Progression of Clinically Suspicious Oral Lesions With STRATICYTE","Inclusion Criteria:\n\n* Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia\u002Foral squamous cell carcinoma\n\nExclusion Criteria:\n\n* Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy","ALL","15 Years","90 Years",{"count":97,"type":98},500,"ESTIMATED","OBSERVATIONAL","The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.",[102],"Oral Neoplasm",[104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135],"Leukoplakia","Erythroplakia","Erythroleukoplakia","Lesion","Oral Epithelial Dysplasia","S100A7 Biomarker","S100A7 Immunohistochemistry Signature-based","Early Diagnosis","STRATICYTE","Oral Neoplasia","Oral Epithelial Atypia","Hyperplasia","Hyperkeratosis","Oral Squamous Cell Carcinoma","Oral Cancer","Potentially Premalignant Oral Epithelial Lesion","OPMD","Mild Dysplasia","Moderate Dysplasia","Severe Dysplasia","Low-grade Dysplasia","High-grade Dysplasia","Personalized Medicine","Predictive Assay","Whole Slide Imaging","Computational Pathology","Digital Pathology","Artificial Intelligence","Machine Learning","OPML","Oral Potentially Malignant Disorder","Oral Potentially Malignant Lesion","2024-11-05",{"date":138,"type":139},"2024-11-07","ACTUAL",{"date":141,"type":139},"2015-03-12",{"date":143,"type":98},"2026-12-31",{"name":5,"class":6},3]